Daniel M Cheney

age ~59

from Haddonfield, NJ

Get Report

Also known as:

Connected to:

Daniel Cheney Phones & Addresses

view source

Author
Daniel P. Cheney

ISBN #
0295959908

view source

Name / Title

Company / Classification

Phones & Addresses

Daniel Cheney
Board of Directors

Lamb Foundation
Individual Family Services · Social Service & Welfare Organ

114 N Main St, North Wales, PA 19454
2156995600, 2156618825

Daniel L. Cheney
Secretary

SPRINGHOUSE FINANCIAL CORPORATION

111 Bethlehem Pike , Spring House, PA 19477

Sulfonyl Amide Inhibitors Of Calcium Channel Function
view source
US Patent:

7504431, Mar 17, 2009
Filed:

Apr 15, 2005
Appl. No.:

11/107218
Inventors:

Jon J. Hangeland - Morrisville PA, US
Daniel L. Cheney - Ringoes NJ, US
Todd J. Friends - Bordentown NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 31/40
C07D 209/04
US Classification:

514428, 514365, 514415, 514534, 548203, 548469, 548530, 560 12
Abstract:

Compounds of formula I.

Macrocyclic Factor Viia Inhibitors Useful As Anticoagulants
view source
US Patent:

7592331, Sep 22, 2009
Filed:

Dec 21, 2006
Appl. No.:

11/614131
Inventors:

Eldon Scott Priestley - Yardley PA, US
Daniel L. Cheney - Ringoes NJ, US
Nicholas Ronald Wurtz - Pennington NJ, US
Peter W. Glunz - Yardley PA, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07D 267/22
C07D 513/00
A61K 31/33
A61K 31/47
A61P 7/02
US Classification:

514183, 514307, 540456, 540460
Abstract:

The present invention relates generally to novel macrocycles of Formula (I):.

Macrocyclic Factor Viia Inhibitors Useful As Anticoagulants
view source
US Patent:

20090281139, Nov 12, 2009
Filed:

Jul 23, 2009
Appl. No.:

12/507907
Inventors:

Eldon Scott Priestley - Yardley PA, US
Daniel L. Cheney - Ringoes NJ, US
Nicolas Ronald Wurtz - Pennington NJ, US
Peter W. Glunz - Yardley PA, US
International Classification:

A61K 31/4725
C07D 245/00
A61P 7/02
US Classification:

514310, 540456, 540460
Abstract:

The present invention relates generally to novel macrocycles of Formula (I):or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, L, M, W, Z, R, R, R, R, R, R, R, R, R, and Rare as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

Azacyclic Bisphosphonates As Anticholesterolemic Agents
view source
US Patent:

53170156, May 31, 1994
Filed:

May 1, 1992
Appl. No.:

7/877574
Inventors:

John W. Ullrich - Philadelphia PA
Raymond D. Youssefyeh - Princeton Junction NJ
Daniel L. Cheney - Audubon PA
Christopher J. Burns - Bryn Mawr PA
Assignee:

Rhone-Poulenc Rorer Pharmaceuticals Inc. - Collegeville PA
International Classification:

A61K 31675
A61K 3166
US Classification:

514 79
Abstract:

This invention relates to a method of lowering abnormally high serum cholesterol levels in the body without significantly reducing mevalonic metabolite synthesis and to novel pharmacological compositions containing as an active ingredient bisphosphonic acid and ester compounds containing a mono-, bi- or tricyclic ring linked with a bisphosphonate moiety through a basic amino alkylene group. This invention also provides novel bisphosphonate compounds and the processes for their preparation.

Substituted (Sulfinic Acid, Sulfonic Acid, Sulfonylamino Or Sulfinylamino) N-[(Aminoiminomethyl)Phenylalkyl]-Azaheterocyclylamide Compounds
view source
US Patent:

56123531, Mar 18, 1997
Filed:

Jun 7, 1995
Appl. No.:

8/481024
Inventors:

William R. Ewing - King of Prussia PA
Michael R. Becker - Norristown PA
Henry W. Pauls - Collegeville PA
Daniel L. Cheney - West Chester PA
Jonathan S. Mason - Dagenham, GB
Alfred P. Spada - Lansdale PA
Assignee:

Rhone-Poulenc Rorer Pharmaceuticals Inc. - Collegeville PA
International Classification:

C07D40102
A61K 3140
A61K 31435
US Classification:

514309
Abstract:

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.